Overview
Samsrita Labs Limited, formerly Dr Habeebullah Life Sciences Limited, is engaged in the bio-pharma sector focusing on drug discovery, stem cell therapy, and molecular diagnostics.
The company has transitioned from its initial focus on stem cell hospitals to include biopharma activities, emphasized by its historical changes in main business objects to incorporate advanced drug discovery and biotechnology research.
It has a strategic collaborative agreement with Krisani Bio Sciences and the Centre for Liver Research and Diagnostics to advance research in NASH and Wilson Disease through revenue-sharing partnerships.
The company focuses on affordable healthcare, reflecting its dedication to advancing RNAi therapeutics, biomarker discovery, and other niche biotechnologies.
Krisani Bio Sciences transformed from a subsidiary to an associate company, altering Samsrita Labs' ownership stake and highlighting strategic restructuring in shareholding.
- Sector
Healthcare Services
- Industry
Healthcare Service Provider
- Market Cap
41 Cr
- Volatility
Low Risk
- P/E Ratio
-5.4
- Industry P/E
56.3
- PEG Ratio
—
- P/B Ratio
2.6
- 52W High
26.04
- 52W Low
13.78
Financial Ratios
Sales CAGR
- 1Y
- —
- 3Y
- —
- 5Y
- —
- 10Y
- —
Profit CAGR
- 1Y
- -4.00%
- 3Y
- —
- 5Y
- —
- 10Y
- —
ROE
- TTM
- -29.86%
- 3Y
- -3.28%
- 5Y
- -0.78%
- 10Y
- -5.25%
ROCE
- TTM
- -30.51%
- 3Y
- -3.26%
- 5Y
- -0.78%
- 10Y
- -5.21%
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
